

# Tobias Hofving

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7111662/publications.pdf>

Version: 2024-02-01

8  
papers

229  
citations

1478505

6  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

425  
citing authors

#	ARTICLE	IF	CITATIONS
1	The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines. <i>Endocrine-Related Cancer</i> , 2018, 25, 367-380.	3.1	58
2	Extreme Female Promiscuity in a Non-Social Invertebrate Species. <i>PLoS ONE</i> , 2010, 5, e9640.	2.5	52
3	Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets. <i>Modern Pathology</i> , 2016, 29, 616-629.	5.5	36
4	NAMPT Inhibitor GMX1778 Enhances the Efficacy of <sup>177</sup> Lu-DOTATATE Treatment of Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2017, 58, 288-292.	5.0	33
5	<sup>177</sup> Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. <i>Endocrine-Related Cancer</i> , 2019, 26, 437-449.	3.1	14
6	SMAD4 haploinsufficiency in small intestinal neuroendocrine tumors. <i>BMC Cancer</i> , 2021, 21, 101.	2.6	7
7	The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion. <i>Cancers</i> , 2021, 13, 4305.	3.7	7
8	H-ST5, L-ST5 and KRI-I are not authentic GEPNET cell lines. <i>Nature Genetics</i> , 2019, 51, 1426-1427.	21.4	4